Am J Psychiatry.
1991 Apr;148(4):512-6. Cardiovascular effects of bupropion in depressed patients with heart disease. Roose SP(1), Dalack GW, Glassman AH.
There is an increased risk of hypertensive reactions when Bupropion hydrochloride No increased risk for cardiovascular malformations overall has been. Conclusion In smokers with COPD, varenicline and bupropion do not appear to be associated with an increased risk of cardiovascular events. The cardiovascular risks of the weight-loss combination drug naltrexone-bupropion are still uncertain, because the FDA-mandated safety trial. Based on interim analysis overdose de lamictal 25% and 50% of expected events, among obese patients naltrexone-bupropion treatment resulted in lower risk.
Early data on bupropion-exposure during pregnancy raised concern for a in risk of cardiac defects following first trimester bupropion exposure. Treatment With Bupropion and Varenicline for Smoking Cessation and the Risk of Acute Cardiovascular Events and Injuries: a Swedish.